UniSuper Management Pty Ltd Has $9.18 Million Stock Position in Pfizer Inc. $PFE

Key Points

• UniSuper Management Pty Ltd increased its stake in Pfizer Inc. by 3.6%, owning 362,283 shares valued at $9.18 million.
• Pfizer's recent earnings report showed an EPS of $0.78, exceeding expectations, with revenue of $14.65 billion for the quarter—a 10.3% increase year-over-year.
• The company announced a quarterly dividend of $0.43 per share, resulting in an annualized dividend yield of 6.9%.

UniSuper Management Pty Ltd boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 362,283 shares of the biopharmaceutical company's stock after purchasing an additional 12,538 shares during the quarter. UniSuper Management Pty Ltd's holdings in Pfizer were worth $9,180,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Bessemer Group Inc. grew its holdings in Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after acquiring an additional 13,228 shares during the period. Capital Advisors Inc. OK boosted its position in shares of Pfizer by 1.2% in the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after purchasing an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Pfizer during the first quarter worth $8,283,000. Alta Advisers Ltd increased its holdings in Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after purchasing an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC lifted its stake in Pfizer by 8.7% in the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after buying an additional 10,051 shares during the period. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the subject of several analyst reports. HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Berenberg Bank decreased their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Jefferies Financial Group increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Up 1.3%

Shares of PFE stock opened at $24.86 on Monday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a fifty day moving average of $24.85 and a 200-day moving average of $24.34. The company has a market capitalization of $141.31 billion, a price-to-earnings ratio of 13.22, a P/E/G ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.